The majority of prostate cancer patients who require endocrine therapy are locally progressive or metastatic cases. The principle of endocrine therapy is to use drugs to lower the level of androgens in the patient’s body, thereby stopping the proliferation and progression of prostate cancer cells. However, studies have shown that some prostate cancer cells can continue to survive despite very low androgen levels. Some of the more malignant tumor cells will continue to develop. This is the main reason why some prostate cancer patients will still have recurrence or even progression of their disease on the basis of endocrine therapy. So in this case, once endocrine therapy is interrupted or stopped, some prostate cancer patients will soon experience a rebound increase in PSA levels, suggesting that some of the tumor cells are back in an active development state, which significantly increases the threat to the patient’s prognosis. In our clinical work, we have also observed that some patients who delayed or stopped endocrine drug therapy due to epidemic and other reasons did find progression in subsequent follow-up visits. Therefore, interruption or discontinuation of endocrine therapy is generally not recommended for patients with prostate cancer who are receiving regular endocrine therapy.